Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oramed Pharmaceuticals (ORMP) Equity Ratio (2022 - 2025)

Oramed Pharmaceuticals (ORMP) has disclosed Equity Ratio for 3 consecutive years, with 0.94 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Equity Ratio rose 46.75% year-over-year to 0.94, compared with a TTM value of 0.94 through Sep 2024, up 46.75%, and an annual FY2023 reading of 0.74, down 21.02% over the prior year.
  • Equity Ratio was 0.94 for Q3 2024 at Oramed Pharmaceuticals, down from 0.96 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.96 in Q2 2023 and bottomed at 0.64 in Q3 2023.
  • Average Equity Ratio over 3 years is 0.89, with a median of 0.94 recorded in 2023.
  • The sharpest move saw Equity Ratio plummeted 31.07% in 2023, then surged 46.75% in 2024.
  • Year by year, Equity Ratio stood at 0.94 in 2022, then fell by 21.02% to 0.74 in 2023, then grew by 27.56% to 0.94 in 2024.
  • Business Quant data shows Equity Ratio for ORMP at 0.94 in Q3 2024, 0.96 in Q2 2024, and 0.81 in Q1 2024.